Litigation Details for Anacor Pharmaceuticals, Inc. v. Lupin Limited (D. Del. 2018)
✉ Email this page to a colleague
Anacor Pharmaceuticals, Inc. v. Lupin Limited (D. Del. 2018)
Docket | ⤷ Sign Up | Date Filed | 2018-10-17 |
Court | District Court, D. Delaware | Date Terminated | 2020-09-11 |
Cause | 35:271 Patent Infringement | Assigned To | Richard Gibson Andrews |
Jury Demand | None | Referred To | |
Patents | 7,582,621; 9,549,938; 9,566,289; 9,566,290; 9,572,823 | ||
Link to Docket | External link to docket |
Small Molecule Drugs cited in Anacor Pharmaceuticals, Inc. v. Lupin Limited
Details for Anacor Pharmaceuticals, Inc. v. Lupin Limited (D. Del. 2018)
Date Filed | Document No. | Description | Snippet | Link To Document |
---|---|---|---|---|
2021-06-23 | 108 | Report and Recommendations | An ancestor to the patents-in-suit, U.S. Patent No. 7,582,621 (“the ’621 patent”), also claimed methods…of U.S. Patent Nos. 9,549,938, 9,566,289, 9,566,290, and 9,572,823 (collectively, the “patents-in- suit… While the IPR of the ʼ621 patent was pending, the patents-in-suit were being prosecuted before… the four patents-in-suit in early 2017 (before the PTAB’s IPR decision on the ʼ621 patent). Anacor listed…review of the patents-in-suit. The PTAB instituted review of all claims of all four patents-in-suit in | External link to document |
>Date Filed | >Document No. | >Description | >Snippet | >Link To Document |